The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

The first day of the CDDF Annual Conference 2024 generated highly productive and vibrant dialogue around critical questions about real world evidence and underscoring the importance of collaborative efforts. Here are the key takeaways from Session 1: Real World Evidence:

🔶There has been rapid growth in the availability of RWD, accompanied by efforts across regulators, academics, data holders, and the pharmaceutical industry to advance appropriate uses whilst working through the strengths and limitations of RWD. Great progress have been made with RWD, however we have significant work and much required alignment amongst key stakeholders.  

🔶Commitment to continuous data improvement and collection is an important step in maximizing the utility of RWD to generate RWE for patient-centred regulatory decision.  RCTs provide defined data, and the premise of RWD through pragmatic trials and robust RWD collection aid decision making, looking at the “totality of data” .

🔶The evolution of registries, Darwin EU and OPTIMA were extensively reviewed, providing insights on how these databases have advanced the RWD field. Harmonisation and robustness of data collection within member states and globally continues to be required to ensure robust RWD to support decision making.

Stay tuned for more updates from the multi-stakeholder conference!

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70